Program
TJ0113
A development code. Also written as “TJ0113 200mg”, “TJ0113 400mg” and “TJ0113 Capsules”.
Its studies are mostly in Depression · Parkinson Disease · Sarcopenia, led by Hangzhou PhecdaMed.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou PhecdaMed | 52 open or running | phase 3since Jul 28, 2026 | Feb 6, 2025 | Aug 22, 2027phase 2 · NCT07620938 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 6, 2025First study: phase 1 study in Healthy Chinese SubjectsFirst studyNCT06832540 · 6 enrolled · China
- Jun 4, 2025Phase 2 study in DepressionNCT07018245 · 149 enrolled · China
- Jan 26, 2026Phase 1 study in Healthy SubjectsNCT07394452 · 130 enrolled · China
- May 27, 2026Phase 2 study in SarcopeniaNCT07620938 · 204 planned · China
- Jul 28, 2026Phase 3 study in Parkinson DiseasePhase 3 reachedNCT07741045 · 300 planned · China
Ahead
- Aug 22, 2027Primary completion: phase 2 study in SarcopeniaNCT07620938
- Jan 15, 2028Primary completion: phase 3 study in Parkinson DiseaseNCT07741045
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07741045Parkinson Disease · China | 3 | Not yet recruiting | Jan 15, 2028 | 300 |
| NCT07620938Sarcopenia · China | 2 | Recruiting | Aug 22, 2027 | 204 |
| NCT07394452Healthy Subjects · China | 1 | Completed | Feb 5, 2024 | 130 |
| NCT07018245Depression · China | 2 | Completed | Jun 25, 2026 | 149 |
| NCT06832540Healthy Chinese Subjects · China | 1 | Completed | Mar 5, 2025 | 6 |
How it is read
Names in the registry
- “TJ0113”, 4 entries
- “TJ0113 200mg”, 1 entry
- “TJ0113 400mg”, 1 entry
- “TJ0113 Capsules”, 1 entry
- “[14C]TJ0113”, 1 entry
Codes read as this program: TJ0113.
Conditions, from the studies’ own filings
- Depression, 1 study
- Parkinson Disease, 1 study
- Sarcopenia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.